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Metabolomic Proﬁling in Relation to New-Onset Atrial
Fibrillation (from the Framingham Heart Study)
Darae Ko, MDa,b,c, Eric M. Riles, MD, MPHd, Ernaldo G. Marcos, MDe, Jared W. Magnani, MD, MScd,
Steven A. Lubitz, MD, MPHf,g, Honghuang Lin, PhDh, Michelle T. Long, MDi,
Renate B. Schnabel, MD, MScj, David D. McManus, MDk, Patrick T. Ellinor, MD, PhDf,g,
Vasan S. Ramachandran, MDb,d,h,l,m, Thomas J. Wang, MDn, Robert E. Gerszten, MDf,
Emelia J. Benjamin, MD, ScMb,d,h,l,m, Xiaoyan Yin, PhDo, and Michiel Rienstra, MD, PhDe,*
Previous studies have shown several metabolic biomarkers to be associated with prevalent
and incident atrial ﬁbrillation (AF), but the results have not been replicated. We investi-
gated metabolite proﬁles of 2,458 European ancestry participants from the Framingham
Heart Study without AF at the index examination and followed them for 10 years for new-
onset AF. Amino acids, organic acids, lipids, and other plasma metabolites were proﬁled by
liquid chromatographyetandem mass spectrometry using fasting plasma samples. We
conducted Cox proportional hazard analyses for association between metabolites and new-
onset AF. We performed hypothesis-generating analysis to identify novel metabolites and
hypothesis-testing analysis to conﬁrm the previously reported associations between me-
tabolites and AF. Mean age was 55.1 – 9.9 years, and 53% were women. Incident AF
developed in 156 participants (6.3%) in 10 years of follow-up. A total of 217 metabolites
were examined, consisting of 54 positively charged metabolites, 59 negatively charged
metabolites, and 104 lipids. None of the 217 metabolites met our a priori speciﬁed Bon-
ferroni corrected level of signiﬁcance in the multivariate analyses. We were unable to
replicate previous results demonstrating associations between metabolites that we had
measured and AF. In conclusion, in our metabolomics approach, none of the metabolites we
tested were signiﬁcantly associated with the risk of future AF.  2016 Elsevier Inc. All
rights reserved. (Am J Cardiol 2016;118:1493e1496)
Previous metabolomics investigations have focused on
identifying metabolic pathways responsible for the initiation
and maintenance of the arrhythmia in patients with known
atrial ﬁbrillation (AF) or postoperative AF.1e13 Recently,
the Atherosclerotic Risk in Communities Study identiﬁed
bile acids glycolithocholate sulfate and glycocholenate
sulfate as markers of increased risk of new-onset AF.14 In
the present study, we aimed to identify novel metabolic
markers and to conﬁrm the association between previously
reported metabolites in relation to new-onset AF.
aSection of General Internal Medicine, dSection of Cardiovascular
Medicine, iSection of Gastroenterology, and lSection of Preventive Medi-
cine, Department of Internal Medicine, Boston Medical Center, Boston
University School of Medicine, Boston, Massachusetts; bWhitaker Car-
diovascular Institute and cClinical and Translational Science Institute,
Boston University School of Medicine, Boston, Massachusetts; eDepart-
ment of Cardiology, University of Groningen, University Medical Center
Groningen, The Netherlands; fCardiovascular Research Center and gCar-
diac Arrhythmia Service, Massachusetts General Hospital, Harvard Medical
School, Boston, Massachusetts; hBoston University and National Heart,
Lung, and Blood Institute’s Framingham Heart Study, Framingham, Mas-
sachusetts; jDepartment of General and Interventional Cardiology, Uni-
versity Heart Center Hamburg Eppendorf, Hamburg, Germany; kDivision
of Cardiovascular Medicine, University of Massachusetts Medical School,
Worcester, Massachusetts; mDepartment of Epidemiology, Boston Uni-
versity School of Public Health, Boston, Massachusetts; nDivision of
Cardiovascular Medicine, Vanderbilt University, Nashville, Tennessee; and
oDepartment of Biostatistics, Boston University School of Public Health,
Boston, Massachusetts. Manuscript received March 31, 2016; revised
manuscript received and accepted August 2, 2016.
Drs. Ko, Riles, and Marcos are co-ﬁrst authors. Drs.Yin and Rienstra
contributed equally to the manuscript.
Funding: Dr. Ko is supported by 5T32HL007224-38 and UL1-
TR000157. Dr. Benjamin is supported in part through NIH/NHLBI
HHSN268201500001I; N01-HC25195, 2R01HL092577, 1R01 HL102214,
1R01HL128914, and 1RC1HL101056. Dr. Ellinor is supported by grants
from the National Institutes of Health (2RO1HL092577, 1K24HL105780),
an Established Investigator Award from the American Heart Association
(13EIA14220013), and the Fondation Leducq (14CVD01). Dr. Lubitz is
supported by an NIH Career Development Award (K23HL114724) and
Doris Duke Charitable Foundation Clinical Scientist Development Award
(2014105). Dr. Magnani is supported by a Doris Duke Charitable Foun-
dation Clinical Scientist Development Award (2015084). Dr. R. Schnabel
has received funding from the European Research Council under the Eu-
ropean Union’s Horizon 2020 research and innovation program (grant
agreement No 648131), German Ministry of Research and Education
(BMBF 01ZX1408A), German Research Foundation Emmy Noether Pro-
gram SCHN 1149/3-1. Dr. Rienstra is supported by a grant from the
Netherlands Organization for Scientiﬁc Research (Veni grant 016.136.055).
The project was funded by NIH R01-DK-HL081572.
See page 1496 for disclosure information.
*Corresponding author: Tel: (þ31) 50-3612355; fax: (þ31) 50-
3614391.
E-mail address: m.rienstra@umcg.nl (M. Rienstra).
0002-9149/16/$ - see front matter  2016 Elsevier Inc. All rights reserved. www.ajconline.org
http://dx.doi.org/10.1016/j.amjcard.2016.08.010
Methods
We studied participants from the Framingham Heart
Study Offspring cohort, which was initiated in 1971.
Participants (n ¼ 5,124) underwent medical and laboratory
evaluation every 4 to 8 years. Our study involved the ﬁfth
examination, consisting of 3,799 participants evaluated from
1991 to 1995. Metabolites were measured on 2,526 partic-
ipants, in whom 49 were excluded because of prevalent AF
and 19 because of missing covariates. Institutional Review
Boards at Boston University Medical Center and Massa-
chusetts General Hospital approved the study protocols. All
participants provided written informed consent.
Fasting EDTA plasma metabolites were analyzed using
targeted liquid chromatographyetandem mass spectrometry
using 3 methods focusing on amino acids and amines,15,16
organic acids,17 and lipids.18 Data were acquired using
either an AB SCIEX 4000 QTRAP triple quadrupole mass
spectrometer (positively charged polar compounds and
lipids) or an AB SCIEX 5500 QTRAP triple quadrupole
mass spectrometer (negatively charged polar compounds).
Brieﬂy, polar, positively charged metabolites were separated
using hydrophobic interaction liquid chromatography and
analyzed using multiple reaction monitoring in the positive
ion mode. Polar, negatively charged compounds, including
central and polar phosphorylated metabolites, were sepa-
rated using a Luna NH2 column (150  2 mm, Luna NH2;
Phenomenex, Torrance, California) and analyzed using
multiple reaction monitoring in the negative ion mode.
Lipids were separated on a Prosphere C4 HPLC column and
underwent full scan mass spectrometer analysis in the pos-
itive ion mode. MultiQuant software version 1.2 (AB
SCIEX, Concord, Ontario, Canada) was used for automated
peak integration and manual review of data quality before
statistical analysis. For all 3 proﬁling platforms, a pooled
plasma sample also was run after every 20 samples, and the
peak areas in samples were normalized to metabolite peak
areas in the nearest pooled plasma. We have previously
published that coefﬁcient of variabilities (CVs) for w80%
of the analytes are <20%.15,17e19
Physicians measured systolic and diastolic blood pressures
twice in seated participants. Medications and tobacco use were
ascertained by self-report. Tobacco use was deﬁned as routine
smoking of 1 cigarettes/day within the year before the
Framingham Heart Study clinic visit. Diabetes was deﬁned by
fasting serum glucose of 126 mg/dl or use of insulin or oral
hypoglycemic agents. Serum lipid and glucose concentrations
were collected after an overnight fast. Myocardial infarction
and heart failure were determined by a panel of 3 physicians
who examined hospital and outpatient records of the partici-
pants, using previously reported criteria.20
The presence of AF was determined from participant
records from the Framingham Heart Study clinic as well as
both other ambulatory clinic and inpatient hospital records
and Holter monitoring. Participants were diagnosed with AF
if either AF or atrial ﬂutter was noted on electrocardiogram.
Cardiologists at the Framingham Heart Study conﬁrmed the
incident AF electrocardiographic diagnoses.
We present baseline characteristics as mean  standard
deviation for continuous covariates and counts (%)
for dichotomous covariates. Each metabolite was rank
normalized before the analysis using Blom’s method.21 For
the 209 metabolites, we used the corrected p values of
0.00024 (0.05/209) for hypothesis generating. For the 8
metabolites previously reported in the literature to be asso-
ciated with AF (b hydroxybuterate,1 glycine,1 phosphocre-
atine,3 glucose,1 creatine,2 alanine,2 glutamine,2 betaine2),
we used the Bonferroni corrected signiﬁcance level of p
0.00625 (0.05/8) for hypothesis testing. We conducted
Cox proportional hazard analyses for association between
baseline metabolite (rank normalized values) and incident
AF, adjusting for age and gender. We additionally adjusted
for height, weight, systolic and diastolic blood pressures,
current tobacco use, antihypertensive medication use, dia-
betes, myocardial infarction, heart failure, and statin use.22
We analyzed 10-year risk of AF by censoring on death,
last contact, or 10 years from examination 5 date, whichever
came ﬁrst. Hazard ratios (HR) are expressed per SD of the
metabolites. Analyses were conducted with SAS version 9.4
software (SAS Institute, Cary, North Carolina).
Results
Baseline characteristics of the study sample are provided
in Table 1. Of 2,458 participants, incident AF developed in
156 participants (6.3%) during 10 years of follow-up. A
total of 217 metabolites were identiﬁed from the baseline
Table 1
Baseline characteristics of study sample
Variable Total Population
(n ¼ 2,477)
Age (years) 55.19.9
Women 1296 (53%)
Height (cm) 1689.3
Weight (kg) 7816
Current smoker 459 (19%)
Systolic blood pressure (mmHg) 12619
Diastolic blood pressure (mmHg) 7510
Antihypertensive medication use 482 (20%)
Statin use 96 (4%)
Diabetes mellitus 169 (7%)
Prevalent heart failure 7 (0.3%)
Prevalent myocardial infarction 51 (2%)
Values are n (%), or mean  SD.
Table 2
Age- and sex-adjusted associations of candidate metabolites with incident
AF
Metabolite Hazard Ratio (95%
conﬁdence interval)*
p Value†
Beta hydroxybuterate 1.07 (0.88-1.29) 0.50
Glycine 1.05 (0.87-1.26) 0.63
Phosphocreatine 0.87 (0.72-1.05) 0.15
Creatine 0.91 (0.77-1.08) 0.28
Alanine 1.16 (0.98-1.36) 0.08
Glutamine 1.01 (0.87-1.18) 0.86
Betaine 1.03 (0.87-1.22) 0.03
Glucose/fructose/galactose 1.39 (1.17-1.65) 0.0002
* Hazard ratio expressed per standard deviation of the metabolite.
† Signiﬁcance level of p 0.00625 (0.05/8) for hypothesis testing.
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samples of the entire cohort, consisting of 54 positively
charged metabolites, 59 negatively charged metabolites, and
104 lipids (Supplementary Table).
In our Cox proportional analysis for association between
previously reported baseline metabolites and incident AF,
only fructose, glucose, and/or galactose met our a priori
speciﬁed Bonferroni corrected level of signiﬁcance when
adjusted for age and gender (Table 2). None of the metab-
olites met our corrected level of signiﬁcance with additional
adjustments.
None of the 217 metabolites met our a priori speciﬁed
Bonferroni corrected level of signiﬁcance with multivariate
adjustments (Supplementary Table).
Given our sample size (n ¼ 2,458) and number of
participants with incident AF, there was 80% of power to
replicate previously reported metabolites with HR 1.37 at
a ¼ 0.00625 level; there was 80% of power to discover
metabolites with HR 1.49 at a ¼ 0.00024 level.
Discussion
In our longitudinal analysis of participants of the Fra-
mingham Heart Study, we found no plasma metabolites to
be associated with the risk of future AF at our a priori
speciﬁed level of signiﬁcance. Both metabolomics and
nonmetabolomics studies have examined associations be-
tween biomarkers and the risk of AF (Table 3). Recently, the
community-based Atherosclerotic Risk in Communities
Study reported associations between serum metabolites
identiﬁed through nontargeted metabolomics approach and
the risk of new-onset AF.14 In their analysis, bile acids,
glycolithocholate sulfate, and glycocholenate sulfate, were
signiﬁcantly associated with the risk of new-onset AF after
multivariate adjustments.14 Our targeted liquid chromatog-
raphyetandem mass spectrometry platform did not detect
either of the metabolites; it detected bile salts, glycocholate,
and glycodeoxycholate, which were not signiﬁcantly asso-
ciated with the risk of new-onset AF. Before the Athero-
sclerotic Risk in Communities Study, Mayr et al.1 identiﬁed
several metabolites using human atrial tissues as potential
markers of increased risk of AF after cardiac surgery, and
De Souza et al.2 found various metabolites using canine
atrial tissues as markers of increased risk of heart fail-
ureeinduced AF (Table 3). Our metabolomics proﬁling did
not conﬁrm the results of the 3 studies.
Additional nonmetabolomics studies have focused on
speciﬁc metabolites and demonstrated signiﬁcant variation
by AF status in the circulating and tissue concentrations of
several metabolites in both animals and humans
(Table 3).3e5,8e10 The molecules studied include phospho-
creatine, cyclic guanosine monophosphate, uric acid, 3-
nitrotyrosine, myoﬁbrillar creatine kinase, glutathione, and
peroxide. Phosphocreatine was detected in our study but
was not signiﬁcantly associated with the risk of new-onset
AF.
Several reasons may explain inconsistency between our
results compared to the previous reports. First, in our liquid
chromatographyetandem mass spectrometry approach, we
may have missed metabolites outside the targeted plat-
form.23 Second, use of a strict threshold for corrected p
values may have masked subtle associations.23 Finally, the
participants, tissues, and study designs were heterogeneous.
Our study examined participants of European ancestry free
of AF at baseline. The studies by Mayr et al. and De Souza
Table 3
Metabolites previously studied
First Author, Year
Metabolite Source
Main Findings
Metabolomics studies
Alonso, 201514
Human serum
Higher incident AF risk associated with higher concentrations of glycolithocholate sulfate and
glycocholenate sulfate
De Souza, 20102
Canine atrial tissue
After 2 weeks of ventricular-tachypacing, ADPþATP, alanine, betaine, glucose, glutamate,
NADþNADH, and taurine levels were increased and a-ketoisovalerate level was decreased
Mayer, 20081
Human atrial tissue
Higher concentrations of b-hydroxybutyrate and glycine in the AF group compared to the
sinus rhythm group
Non-metabolomics studies
Tamariz, 20115
Human serum
Higher risk of AF associated with higher uric acid concentration
Neuman, 20079
Human plasma
Increased oxidation of glutathione and derivatives of reactive oxygen metabolites in the AF
group compared to control
Ramlawai, 200710
Human atrial tissue, serum
Tissue: Higher peroxide level in the AF group compared to control
Serum: Higher peroxide level in the AF group at 6 hours after surgery but not at post-operative
day 4
Mihm, 20018
Human atrial tissue
MM-CK activity was reduced and 3-nitrotyrosine concentration was increased in the AF group
compared to control
Ausma, 20003
Goat atrial tissue
Phosphocreatine level dropped during the ﬁrst 8 weeks of AF induction and then returned to
normal at 16 weeks; levels of creatine, ATP, ADP, AMP, GDP, GTP, and NAD did not
change signiﬁcantly.
Uno, 19864
Canine plasma
cGMP concentration increased signiﬁcantly with AF induction; cAMP concentration did not
change
ADP ¼ adenosine diphosphate; AF ¼ atrial ﬁbrillation; ATP ¼ adenosine triphosphate; cAMP ¼ cyclic (c) adenosine monophosphate (AMP);
cGMP ¼ cyclic (c) guanosine monophosphate (GMP); GDP ¼ guanosine diphosphate; GTP ¼ guanosine triphosphate; MM-CK ¼ myoﬁbrillar creatine
kinase; NADH ¼ nicotinamide adenine dinucleotide (NAD) þ hydrogen (H).
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et al. were both cross-sectional in design. The Atheroscle-
rotic Risk in Communities Study analyzed African-
Americans free of AF at baseline. The study by Mayr
et al. examined the risk of postoperative AF among the
patients undergoing cardiac surgery. De Souza et al. used an
animal model to investigate heart failureeinduced AF.
There are several limitations to our study. First, metab-
olite proﬁles may be tissue speciﬁc; sampling from the
plasma may have failed to detect metabolite associations in
other samples such as serum or at the atrial tissue level.23
Second, we may have underestimated new-onset AF
because AF is frequently clinically unrecognized. Third, the
CVs of some of the metabolites may have led to a sub-
stantial misclassiﬁcation which may have biased the results
toward the null. Fourth, we may have had modest power to
detect small effect sizes. Fifth, our study predominantly
included middle-aged to older subjects of European
ancestry, which may not generalize to other ethnicities or
age groups. There is some evidence that metabolomics
patterns differ by race.24,25 Finally, our AF population in-
cludes all types of AF, and we may have missed association
between the metabolites with speciﬁc AF subtypes such as
atrial ﬂutter, paroxysmal, persistent, or permanent AF.
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